210 related articles for article (PubMed ID: 27031887)
21. Prostate cancer screening: and yet it moves!
Kwiatkowski M; Randazzo M; Kluth L; Manka L; Huber A; Recker F
Asian J Androl; 2015; 17(3):437-8. PubMed ID: 25532573
[TBL] [Abstract][Full Text] [Related]
22. Prostate-specific antigen: does the current evidence support its use in prostate cancer screening?
Duffy MJ
Ann Clin Biochem; 2011 Jul; 48(Pt 4):310-6. PubMed ID: 21525152
[TBL] [Abstract][Full Text] [Related]
23. PSA density improves prediction of prostate cancer.
Verma A; St Onge J; Dhillon K; Chorneyko A
Can J Urol; 2014 Jun; 21(3):7312-21. PubMed ID: 24978363
[TBL] [Abstract][Full Text] [Related]
24. Recent Trends in PSA Testing and Prostate Cancer Incidence: A Look at Context.
Etzioni R; Gulati R
JAMA Oncol; 2016 Jul; 2(7):955-6. PubMed ID: 27010657
[No Abstract] [Full Text] [Related]
25. Serum levels of PSA, ALP, ICTP, and BSP in prostate cancer patients and the significance of ROC curve in the diagnosis of prostate cancer bone metastases.
Wei RJ; Li TY; Yang XC; Jia N; Yang XL; Song HB
Genet Mol Res; 2016 Jun; 15(2):. PubMed ID: 27323113
[TBL] [Abstract][Full Text] [Related]
26. [Comment on Grond, A., M. Ostermann-Myrau: Benign and malignant diseases of the prostate].
Grond A
Versicherungsmedizin; 1995 Apr; 47(2):66-7. PubMed ID: 7539193
[No Abstract] [Full Text] [Related]
27. It ain't what you do, it's the way you do it: five golden rules for transforming prostate-specific antigen screening.
Vickers A; Carlsson S; Laudone V; Lilja H
Eur Urol; 2014 Aug; 66(2):188-90. PubMed ID: 24411991
[TBL] [Abstract][Full Text] [Related]
28. Time to replace prostate-specific antigen (PSA) with the Prostate Health Index (PHI)? Yet more evidence that the PHI consistently outperforms PSA across diverse populations.
Loeb S
BJU Int; 2015 Apr; 115(4):500. PubMed ID: 25808708
[No Abstract] [Full Text] [Related]
29. Prostate specific antigen. Current clinical application and future prospects.
Duskova K; Vesely S
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Mar; 159(1):18-26. PubMed ID: 25277491
[TBL] [Abstract][Full Text] [Related]
30. [New challenges and earlier approved methods in the laboratory diagnosis of prostate cancer].
Kovács GL
Magy Onkol; 2014 Dec; 58(4):301-9. PubMed ID: 25517448
[TBL] [Abstract][Full Text] [Related]
31. The role of PSA and percent free PSA for staging and prognosis prediction in clinically localized prostate cancer.
Pannek J; Partin AW
Semin Urol Oncol; 1998 Aug; 16(3):100-5. PubMed ID: 9741413
[TBL] [Abstract][Full Text] [Related]
32. Biomarkers for early prostate cancer detection.
Margreiter M; Stangelberger A; Valimberti E; Herwig R; Djavan B
Minerva Urol Nefrol; 2008 Mar; 60(1):51-60. PubMed ID: 18427435
[TBL] [Abstract][Full Text] [Related]
33. Patient knowledge about prostate-specific antigen (PSA) and prostate cancer in Australia.
Pan D; McCahy P
BJU Int; 2012 Apr; 109 Suppl 3():52-6. PubMed ID: 22458495
[TBL] [Abstract][Full Text] [Related]
34. [Prostate cancer screening: no proof of the benefit].
Laplanche A; Hill C
Presse Med; 2009 Oct; 38(10):1393-5. PubMed ID: 19647979
[No Abstract] [Full Text] [Related]
35. Diagnosis of prostate cancer: the implications and proper utilization of PSA and its variants; indications and use of MRI and biomarkers.
Law KW; Nguyen DD; Barkin J; Zorn KC
Can J Urol; 2020 Feb; 27(27 Suppl 1):3-10. PubMed ID: 32101694
[TBL] [Abstract][Full Text] [Related]
36. Positive predictive value of prostate biopsy indicated by prostate-specific-antigen-based prostate cancer screening: trends over time in a European randomized trial*.
Bokhorst LP; Zhu X; Bul M; Bangma CH; Schröder FH; Roobol MJ
BJU Int; 2012 Dec; 110(11):1654-60. PubMed ID: 23043563
[TBL] [Abstract][Full Text] [Related]
37. [Estimating standard performance measures of opportunistic screening for prostate cancer].
Leoni M; Falcini F; Ravaioli A; Foca F; Andalò G; Benini F; Dal Pozzo C; Ricci R; Naldoni C; Bucchi L
Epidemiol Prev; 2008; 32(6):285-93. PubMed ID: 19353962
[TBL] [Abstract][Full Text] [Related]
38. [Emerging biomarkers for the diagnosis, staging and prognosis of prostate cancer].
Mazzola CR; Ghoneim T; Shariat SF
Prog Urol; 2011 Jan; 21(1):1-10. PubMed ID: 21193139
[TBL] [Abstract][Full Text] [Related]
39. Optimizing prostate cancer screening; prospective randomized controlled study of the role of PSA and PCA3 testing in a sequential manner in an opportunistic screening program.
Rubio-Briones J; Casanova J; Dumont R; Rubio L; Fernandez-Serra A; Casanova-Salas I; Domínguez-Escrig J; Ramírez-Backhaus M; Collado A; Gómez-Ferrer A; Iborra I; Monrós JL; Ricós JV; Solsona E; Salas D; Martínez F; Lopez-Guerrero JA
Actas Urol Esp; 2014 May; 38(4):217-23. PubMed ID: 24169211
[TBL] [Abstract][Full Text] [Related]
40. Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma.
Stock RG; Stone NN; DeWyngaert JK; Lavagnini P; Unger PD
Cancer; 1996 Jun; 77(11):2386-92. PubMed ID: 8635111
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
